Skip to main content
Home
  • 服务
    服务

    我们的服务涵盖产品开发和商业化的整个生命周期,既适用于小型本地试验,也适用于大型全球项目。

    Read More
    临床研究服务 商业定位 咨询服务 早期服务 战略性解决方案 语言服务 实验室服务 医学影像服务 真实世界洞察 研究中心及患者解决方案
    clinical-trials-china.jpeg
    COVID-19的临床试验

    Clinical trials during COVID-19.

    clinical-trials-china-2.jpeg
    研究中心和患者

    研究中心和患者识别,入组和参与

  • 治疗领域
    治疗领域

    我们在广泛的治疗领域拥有丰富的经验。我们管理所有主要地区的研究,与世界领先的研究人员建立了稳固的工作关系。

    Read More
    心血管系统 细胞和基因疗法(CGT) 中枢神经系统 内分泌与代谢疾病 感染性疾病 内科与免疫学 医疗器械 肿瘤学 儿科学 罕见病与孤儿病 移植免疫学 女性健康
    icon-china-mega-menu-image.jpeg
    疫苗

    ICON 领导了 18 种疫苗的开发,获得了 FDA/EMA 的批准,其中包括世界上第一个获批的 COVID-19 疫苗

    icon-china-mega-menu-image-2.jpeg
    治疗领域洞察

    ICON 的治疗专家定期为行业出版物内容做出贡献。

  • 加入我们
  • 新闻和活动
  • ICON中国
    ICON中国
    Read More
    ICON中国 公司历史 我们的荣誉 Leadership 联系我们
    esg-mdd.jpg
    环境、社会与公司治理(ESG)

    ICON Cares 代表我们致力于关爱每一个人、环境与社区,并带来积极改变的承诺。

    healthcare-intelligence-video-poster.png
    医疗智能赋能

    推动临床研究不断前行

  • 中国大陆办公室
  • 商务合作
  1. Home
  2. 新闻和活动
  3. 活动一览
  4. Webinars
  5. What's Next in eCOA?

What's Next in eCOA?

New insights into equivalence testing methodology and implications for BYOD

  • Date 16 November 2017
    Time 16:00 - 17:00
    Location Webinar
    Timezone Europe/London

On-Demand Webinar Archive

To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.

Access Webinar Archive

Overview

In this webinar, we review the accumulating evidence to support measurement equivalence of instruments when migrated to ePRO. We review meta analyses of published quantitative equivalence studies, and a newly published meta synthesis of unpublished cognitive interview studies on over 100 instruments performed by ICON.

These meta analyses provide strong evidence that the measurement properties of instrument migrations that follow ePRO design best practice are unaffected by migration from paper to electronic formats, and provide greater insights to the definition of migration best practice.

While this provides support for the use of bring your own device (BYOD) where instrument properties on mobile device models cannot be tested a priori, we also present new results from the industry’s first definitive BYOD quantitative equivalence study, where we assessed instrument measurement properties between paper, BYOD and provisioned devices. We will propose how the results of this study can be generalized to provide support for the use of BYOD in regulatory submission studies.

Because many PRO instruments were developed and validated on paper, care is needed when migrating them to electronic formats (ePRO) to ensure the measurement properties of the instrument are unchanged, and that the electronic version is easy to use in the target group of patients.

In 2009, the ISPOR ePRO Good Research Practices Task Force published recommendations on the evidence needed to support measurement equivalence when migrating from paper to electronic formats, which included cognitive interview and usability testing (minor modifications due to migration) and quantitative equivalence studies (moderate changes).

These recommendations have been largely adopted by the industry and regulators. However, over the 8 years since their publication, accumulating evidence has indicated that instrument measurement properties are generally well conserved when instruments are migrated to electronic forms where ePRO design best practice is followed. Does this mean that a qualitative or quantitative study may not always be needed when implementing ePRO?

Key speakers

Bill Byrom, PhD

Sr. Director Product Innovation, ICON

Bill serves as a Senior Director within Product Innovation at ICON, focusing on harnessing new technologies for clinical trials. He has worked in the Pharma industry for over 25 years and is the author of 60+ publications and an industry textbook on electronic Patient Reported Outcomes. Bill contributes to the C-PATH ePRO Consortium and the eClinical Forum. He holds a PhD in disease simulation.

Willie Muehlhausen, DVM

Head of Innovation, ICON Clinical Research

Willie has been involved in clinical research for more than 20 years and has held positions in Data Management, Clinical Research Operations and Project Management, Business Development and Product Management and Innovation. During his career he has specialised in developing new products and services for CROs and technology providers. He has represented the ePRO vendors as the inaugural Vice Chair of the ePRO consortium and overseen the development of important guidelines regarding the development and migration of questionnaires from paper to electronic formats.

Target audience

  • Professionals working in the field of Outcomes Research e.g. PRO, ePRO, eCOA, COA.
  • Pharmaceutical clinical development.
  • All instrument authors and license holders 
In this section
In this section
  • In the News
  • Press releases
  • 活动一览
    • Industry events
    • Webinars
    • Workshops
  • DIA China 2022

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media
Site Branding
    ICON plc
  • Contact
  • Results & Reports
For Clients
  • 我们的服务
  • 治疗领域
ICON for
  • 新 闻
  • 加入我们
News & Events
  • 中国大陆办公室
  • 商务合作
Socials
  • WeChat QR code

Legal Footer

  • © 2025 ICON plc
  • Disclaimer
  • Privacy
  • Cookies
How can we help?
  • All
Popular search terms:
  • COVID-19
  • Site & Patient Recruitment
  • Oncology
  • Medical Device
  • Real World Evidence
  • Decentralised & hybrid clinical trials
  • Digital Disruption